^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colon Cancer
    Drug:oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    07/01/2020
    Excerpt:
    Recommendations: Patients with high-risk stage II (pT4 or <12 lymph nodes or multiple intermediate risk factors, regardless of MSI) may be considered for the addition of oxaliplatin [I, C].
    DOI:
    10.1016/j.annonc.2020.06.022